Search research articles
Contact Us
Filters
Showing results (31-40 of 621) with videos related to
Page
of 63
Sort By:
The Lancet. Rheumatology
|
August 15, 2025
Further progression in patients with systemic sclerosis-associated interstitial lung disease - Authors' reply
Anna-Maria Hoffmann-Vold, Oliver Distler,
The Journal of Rheumatology
|
July 15, 2025
Personalizing Management of Systemic Sclerosis-Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?
Cosimo Bruni, Muriel Elhai, Oliver Distler
RMD Open
|
August 4, 2016
Treatment of systemic sclerosis: is there any hope for the future?
Yannick Allanore, Marco Matucci-Cerinic, Oliver Distler
The New England Journal of Medicine
|
October 17, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply
Oliver Distler, Martina Gahlemann, Toby M Maher
Vascular Pharmacology
|
December 13, 2012
The Fra-2 transgenic mouse model of systemic sclerosis
Britta Maurer, Jörg H W Distler, Oliver Distler
Current Opinion in Pharmacology
|
June 11, 2013
Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
Milos Antic, Jörg H W Distler, Oliver Distler
Current Rheumatology Reports
|
November 3, 2010
Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials
Naoki Iwamoto, Jörg H W Distler, Oliver Distler
Current Opinion in Rheumatology
|
March 28, 2012
Innovative antifibrotic therapies in systemic sclerosis
Christian Beyer, Oliver Distler, Jörg H W Distler
Swiss Medical Weekly
|
April 27, 2010
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Christian Beyer, Jörg H W Distler, Oliver Distler
RMD Open
|
July 19, 2018
Haematopoietic stem cell transplantation in systemic sclerosis
Ulrich A Walker, Lesley Ann Saketkoo, Oliver Distler
Page
of 63
Search research articles
Search
Showing results (31-40 of 621) with videos related to
Sort By:
Page
of 63
The Lancet. Rheumatology
|
August 15, 2025
Further progression in patients with systemic sclerosis-associated interstitial lung disease - Authors' reply
Anna-Maria Hoffmann-Vold, Oliver Distler,
The Journal of Rheumatology
|
July 15, 2025
Personalizing Management of Systemic Sclerosis-Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?
Cosimo Bruni, Muriel Elhai, Oliver Distler
RMD Open
|
August 4, 2016
Treatment of systemic sclerosis: is there any hope for the future?
Yannick Allanore, Marco Matucci-Cerinic, Oliver Distler
The New England Journal of Medicine
|
October 17, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply
Oliver Distler, Martina Gahlemann, Toby M Maher
Vascular Pharmacology
|
December 13, 2012
The Fra-2 transgenic mouse model of systemic sclerosis
Britta Maurer, Jörg H W Distler, Oliver Distler
Current Opinion in Pharmacology
|
June 11, 2013
Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
Milos Antic, Jörg H W Distler, Oliver Distler
Current Rheumatology Reports
|
November 3, 2010
Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials
Naoki Iwamoto, Jörg H W Distler, Oliver Distler
Current Opinion in Rheumatology
|
March 28, 2012
Innovative antifibrotic therapies in systemic sclerosis
Christian Beyer, Oliver Distler, Jörg H W Distler
Swiss Medical Weekly
|
April 27, 2010
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Christian Beyer, Jörg H W Distler, Oliver Distler
RMD Open
|
July 19, 2018
Haematopoietic stem cell transplantation in systemic sclerosis
Ulrich A Walker, Lesley Ann Saketkoo, Oliver Distler
Page
of 63